Rosa Nguyen, M.D., Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10-CRC, Room 1-5816
- Bethesda, MD 20892
Dr. Nguyen is a pediatric oncologist and physician-scientist specializing in the discovery and preclinical development of immunotherapies for the treatment of children with neuroblastoma. She earned her M.D. from the University of Hamburg, Germany, and completed her pediatric residency at the University of Maryland and her pediatric hematology-oncology fellowship training at St. Jude Children’s Research Hospital. Subsequently, she obtained her Ph.D. under the mentorship of Dr. Michael A. Dyer, studying natural killer cells and their therapeutic role in pediatric cancer.
Areas of Expertise
1) monoclonal antibody therapy 2) cytokine biology 3) natural killer (NK) cell biology 4) adoptive CAR T therapy 5) mouse modeling
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
The goal of my laboratory is to apply innovative experimental systems to develop novel immunotherapies for patients with neuroblastoma. I am committed to creating an environment in my laboratory where everyone has an equal opportunity to succeed. I believe that diversity is integral to fostering a productive work environment for scientific discovery and collaboration, and I look forward to serving as a mentor to students and post-doctoral fellows. My laboratory focuses on two main areas:
1. Harnessing tumor-targeting antibodies and NK cell activity in pediatric solid tumors
We developed next-generation antibody cytokine fusion proteins and will assess their therapeutic efficacy in preclinical neuroblastoma models. The aim of these studies is to translate these novel antibody cytokine fusion proteins to an investigator-initiated clinical trial for GD2-expressing malignancies.
2. Optimizing cell-based immunotherapy for pediatric neuroblastoma:
We have demonstrated preclinical activity of GPC2-targeting chimeric antigen receptor (CAR) T cell therapy in preclinical neuroblastoma models. This work will be translated into an investigator-initiated first-in-human clinical trial for patients with neuroblastoma in the Pediatric Oncology Branch. To further optimize CAR T cell therapy, our laboratory focuses on CAR engineering to manipulate the CAR structure, conditionally alter CAR expression, and exploit the use of transgenic cytokines. We use genome-wide CRISPR screens to understand the mechanisms of tumor response to and evasion from adoptive CAR T therapy. Altogether, these efforts are geared towards finding new adoptive therapies to treat patients with neuroblastoma.
Next-generation humanized patient-derived xenograft mouse model for pre-clinical antibody studies in neuroblastoma
Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial
Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia
Rosa Nguyen, M.D., Ph.D.
I obtained my medical degree from the University of Hamburg and subsequently moved to the U.S. to complete my pediatric residency at the University of Maryland and my subspecialty training in pediatric hematology-oncology at St. Jude Children’s Research Hospital. As a second-year fellow, I enrolled at the University of Tennessee Health Science Center to pursue a Ph.D. degree in biomedical sciences with Dr. Michael A. Dyer. Following the completion of my Ph.D. studies, I trained as a postdoctoral fellow with Dr. Warren J. Leonard and later with Dr. Carol J. Thiele.
I am the recipient of the 2018 Conquer Cancer ASCO Young Investigator Award. My work has also been funded by the Department of Defense Peer-Reviewed Cancer Research Program.
There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.
Learn more about CCR research advances, new discoveries and more on our news section.